Founded in 2008, Qurient takes a pioneering position in the newly emerging biotech industry in Korea. Qurient introduced a unique virtual biotech model, running R&D operations not only in clinical development phases, but also in early discovery research stage, named ‘Network R&D’ model. Network R&D aims to capital efficient innovation, being able to tackle on new scientific innovations in various therapeutic areas through experts network. Qurient mainly engages in value creation between early discovery to clinical proof-of-concept. The particular concentration in the value chain creates more efficient organizational structure with clear focus on innovation. Qurient believes late stage development is better handled by fully integrated pharmaceutical/biotech industry with proper marketing function in the therapeutic area. Qurient’s mission is to provide innovation for unmet medical needs to help patients around the world. Through fulfilling the mission, Qurient will be able to create concrete value for its shareholders.

Q203 : A tuberculosis treatment currently nearing regulatory clinical trial entry. Q702 : An immunotherapy cancer drug, currently in clinical trials in combination with Merck's Keytruda (MSD), showing efficacy in Phase 2 trials. Q901 : A novel anticancer therapy based on CDK7 inhibition, with research results to be presented at the American Association for Cancer Research in April 2024. It has the potential to transform the landscape of cancer treatments.

Public

Biotech